• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Superior outcome of upfront allogeneic hematopoietic cell transplantation versus hypomethylating agent induction in myelodysplastic syndrome.

作者信息

Schroeder Jan Christian, Mix Lucas, Faustmann Philipp, Weller Jan Frederic, Fehn Adrian, Phely Laurent, Riedel Andreas, Vogel Wichard, Faul Christoph, Lengerke Claudia, Bethge Wolfgang Andreas

机构信息

Department for Internal Medicine 2, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tuebingen, Tuebingen, Germany.

出版信息

Bone Marrow Transplant. 2024 Sep;59(9):1332-1334. doi: 10.1038/s41409-024-02365-5. Epub 2024 Jul 9.

DOI:10.1038/s41409-024-02365-5
PMID:38982155
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11368806/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78d6/11368806/0bc5424eb19b/41409_2024_2365_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78d6/11368806/0bc5424eb19b/41409_2024_2365_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/78d6/11368806/0bc5424eb19b/41409_2024_2365_Fig1_HTML.jpg

相似文献

1
Superior outcome of upfront allogeneic hematopoietic cell transplantation versus hypomethylating agent induction in myelodysplastic syndrome.与低甲基化药物诱导相比，初治异基因造血细胞移植治疗骨髓增生异常综合征的疗效更佳。
Bone Marrow Transplant. 2024 Sep;59(9):1332-1334. doi: 10.1038/s41409-024-02365-5. Epub 2024 Jul 9.
2
Molecular alterations monitoring in myelodysplastic patients receiving an allogeneic hematopoietic stem cell transplantation after a reduced-intensity conditioning regimen.在接受减低强度预处理方案后的异基因造血干细胞移植的骨髓增生异常综合征患者中进行分子改变监测。
Bone Marrow Transplant. 2024 Sep;59(9):1309-1312. doi: 10.1038/s41409-024-02314-2. Epub 2024 May 23.
3
A phase 1 dose-escalation study of low-dose lenalidomide maintenance post-allogeneic stem cell transplantation for high-risk acute myeloid leukaemia or myelodysplastic syndrome.一项针对高危急性髓系白血病或骨髓增生异常综合征患者异基因干细胞移植后使用低剂量来那度胺维持治疗的1期剂量递增研究。
Bone Marrow Transplant. 2024 Jul;59(7):1025-1027. doi: 10.1038/s41409-023-02195-x. Epub 2024 Mar 27.
4
Feasibility of hypomethylating agents followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome.低甲基化剂联合异基因造血细胞移植治疗骨髓增生异常综合征患者的可行性。
Bone Marrow Transplant. 2012 Mar;47(3):374-9. doi: 10.1038/bmt.2011.86. Epub 2011 Apr 11.
5
Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34 Selected and Unmodified Hematopoietic Stem Cell Transplantation.异基因造血干细胞移植治疗中高危骨髓增生异常综合征：CD34 分选与未修饰造血干细胞移植的疗效比较。
Biol Blood Marrow Transplant. 2018 May;24(5):1079-1087. doi: 10.1016/j.bbmt.2018.01.001. Epub 2018 Jan 8.
6
Which Patients Should Undergo Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes, and When Should We Do It?哪些骨髓增生异常综合征患者应接受异基因干细胞移植，以及我们应该何时进行移植？
Clin Lymphoma Myeloma Leuk. 2015 Jun;15 Suppl:S43-9. doi: 10.1016/j.clml.2015.04.002.
7
Pretransplantation therapy with hypomethylating agents in patients with myelodysplastic syndromes receiving reduced-intensity conditioning regimens.接受减低强度预处理方案的骨髓增生异常综合征患者的移植前低甲基化药物治疗
Biol Blood Marrow Transplant. 2014 Sep;20(9):1260-1. doi: 10.1016/j.bbmt.2014.07.006. Epub 2014 Jul 11.
8
Comparison between Upfront Transplantation and different Pretransplant Cytoreductive Treatment Approaches in Patients with High-Risk Myelodysplastic Syndrome and Secondary Acute Myelogenous Leukemia.高危骨髓增生异常综合征和继发性急性髓性白血病患者 upfront 移植与不同移植前细胞减灭治疗方法的比较。
Biol Blood Marrow Transplant. 2019 Aug;25(8):1550-1559. doi: 10.1016/j.bbmt.2019.03.011. Epub 2019 Mar 15.
9
Upfront allogeneic stem cell transplantation after reduced-intensity/nonmyeloablative conditioning for patients with myelodysplastic syndrome: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire.低强度/非清髓性预处理后 upfront 异基因干细胞移植治疗骨髓增生异常综合征患者：法国骨髓移植和细胞治疗协会的一项研究
Biol Blood Marrow Transplant. 2014 Sep;20(9):1349-55. doi: 10.1016/j.bbmt.2014.05.010. Epub 2014 May 14.
10
Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.改良国际预后评分系统（IPSS-R）在前次异基因造血干细胞移植后并不能改善骨髓增生异常综合征患者的移植后结局：单中心经验。
Biol Blood Marrow Transplant. 2018 Jun;24(6):1209-1215. doi: 10.1016/j.bbmt.2018.02.007. Epub 2018 Feb 20.

引用本文的文献

1
Comparative Analysis of IPSS, IPSS-R, and WPSS for Predicting Survival and Leukemic Transformation in Myelodysplastic Neoplasms: A Real-World Single-Center Experience.国际前列腺症状评分（IPSS）、修订版国际前列腺症状评分（IPSS-R）和世界卫生组织前列腺症状评分（WPSS）预测骨髓增生异常综合征生存和白血病转化的比较分析：一项单中心真实世界研究。
J Clin Med. 2025 Aug 14;14(16):5757. doi: 10.3390/jcm14165757.
2
Advances and Challenges in the Management of Myelodysplastic Syndromes.骨髓增生异常综合征治疗的进展与挑战
Cancers (Basel). 2025 Jul 25;17(15):2469. doi: 10.3390/cancers17152469.
3
Hematopoietic Stem Cell Transplant in Adult Patients with Fanconi Anemia: A Review.

本文引用的文献

1
Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial.复发或反应不佳的急性髓系白血病患者的缓解诱导与立即进行异基因造血干细胞移植（ASAP）：一项随机、开放标签、3期、非劣效性试验。
Lancet Haematol. 2024 May;11(5):e324-e335. doi: 10.1016/S2352-3026(24)00065-6. Epub 2024 Apr 4.
2
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.成人 AML 的诊断与治疗：ELN 专家组代表发布的 2022 年国际专家建议
Blood. 2022 Sep 22;140(12):1345-1377. doi: 10.1182/blood.2022016867.
3
成人范可尼贫血患者的造血干细胞移植：综述
Diseases. 2025 Jun 25;13(7):195. doi: 10.3390/diseases13070195.
4
Allogeneic Stem Cell Transplantation: The Relevance of Conditioning Regime Intensity for Myelodysplastic Syndromes (MDS).异基因干细胞移植：预处理方案强度对骨髓增生异常综合征（MDS）的相关性
Curr Oncol. 2025 May 30;32(6):319. doi: 10.3390/curroncol32060319.
5
Allogeneic hematopoietic cell transplantation in elderly patients with myelodysplastic syndromes: Considerations and challenges.老年骨髓增生异常综合征患者的异基因造血细胞移植：考量与挑战
Semin Hematol. 2024 Dec;61(6):420-430. doi: 10.1053/j.seminhematol.2024.10.004. Epub 2024 Oct 17.
Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study).
5-氮杂胞苷治疗与供者情况的异基因造血干细胞移植在老年进展性 MDS 患者中的比较（VidazaAllo 研究）。
J Clin Oncol. 2021 Oct 20;39(30):3318-3327. doi: 10.1200/JCO.20.02724. Epub 2021 Jul 20.
4
Upfront transplantation may have better outcomes than pretransplant cytoreductive therapy for treating patients with MDS-EB-1 or MDS-EB-2.对于 MDS-EB-1 或 MDS-EB-2 患者， upfront 移植可能比移植前细胞减少治疗有更好的疗效。
Int J Cancer. 2021 Sep 1;149(5):1109-1120. doi: 10.1002/ijc.33608. Epub 2021 May 28.
5
Comparison between Upfront Transplantation and different Pretransplant Cytoreductive Treatment Approaches in Patients with High-Risk Myelodysplastic Syndrome and Secondary Acute Myelogenous Leukemia.高危骨髓增生异常综合征和继发性急性髓性白血病患者 upfront 移植与不同移植前细胞减灭治疗方法的比较。
Biol Blood Marrow Transplant. 2019 Aug;25(8):1550-1559. doi: 10.1016/j.bbmt.2019.03.011. Epub 2019 Mar 15.
6
Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel.异基因造血干细胞移植治疗骨髓增生异常综合征和慢性粒-单核细胞白血病：国际专家小组的建议
Blood. 2017 Mar 30;129(13):1753-1762. doi: 10.1182/blood-2016-06-724500. Epub 2017 Jan 17.
7
Should cytoreductive treatment be performed before transplantation in patients with high-risk myelodysplastic syndrome?对于高危骨髓增生异常综合征患者，是否应在移植前进行减瘤治疗？
J Clin Oncol. 2013 Jul 20;31(21):2761-2. doi: 10.1200/JCO.2012.48.0525. Epub 2013 Jun 17.
8
Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.多中心、随机、开放标签、III 期临床试验，比较地西他滨与患者选择的支持治疗或低剂量阿糖胞苷治疗新诊断的老年急性髓系白血病，患者选择方案由医生提供建议。
J Clin Oncol. 2012 Jul 20;30(21):2670-7. doi: 10.1200/JCO.2011.38.9429. Epub 2012 Jun 11.
9
Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine.60-70 岁初治高危骨髓增生异常综合征或继发性急性髓系白血病患者的异基因造血细胞移植：与未找到供体而接受阿扎胞苷治疗的患者比较。
Biol Blood Marrow Transplant. 2012 Sep;18(9):1415-21. doi: 10.1016/j.bbmt.2012.05.003. Epub 2012 May 11.
10
Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.采用基于 FLAMSA 的大剂量序贯预处理方案对高危骨髓增生异常综合征或继发性急性髓系白血病患者进行 upfront 同种异体造血干细胞移植。
Biol Blood Marrow Transplant. 2012 Mar;18(3):466-72. doi: 10.1016/j.bbmt.2011.09.006. Epub 2011 Sep 29.